The Congress has applied for accreditation by the European Accreditation Council for Continuing Medical Education (EACCME). Attendees will receive a certificate of attendance at the end of the Congress.
Who Should Attend
This educational activity is intended for medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, and other physicians, clinicians, physicians-in-training, and healthcare professionals (nurses, pharmacists, physician assistants, etc.) involved and interested in the therapeutic management of patients with lung cancer.
After successful completion of this course, participants should be able to:
- Evaluate the use of biomarkers for the molecular diagnosis of lung cancer and to predict the efficacy of targeted agents
- Describe and evaluate emerging early detection strategies for lung cancer in Europe
- Compare and contrast invasive versus non-invasive (MRI, CT, PET) procedures in the staging of lung cancer
- Discuss issues and controversies related to the evolving treatment paradigms in front line metastatic NSCLC
- Examine the role of radiotherapy and emerging radiotherapeutic techniques in lung cancer
- Summarize the clinical use of systemic therapies in early-stage lung cancer treatment and incorporate them into practice
- Describe new agents in the treatment of thoracic malignancies, and increase the frequency with which biologically distinct patients are enrolled into appropriate clinical trials
- Analyze the current therapeutic management of mesothelioma and unique populations of patients with thoracic malignancies throughout Europe
Amsterdam RAI Convention Centre
1078 GZ Amsterdam
P.O. Box 77777
1070 MS Amsterdam, The Netherlands
T +31 (0)20 549 12 12
F +31 (0)20 646 44 69
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
For registration inquiries:
Tel.: +1 855-276-6855
©2012 Imedex®, LLC. All rights reserved.
Reproduction in whole or part is prohibited without prior written consent
from Imedex and contributing faculty.